XOMA has built a significant portfolio of products that are licensed to and being developed by other biotechnology and pharmaceutical companies. The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. Many of these licenses are the result of XOMA’s pioneering efforts in the discovery and development of antibody therapeutics. The Company’s royalty-aggregator business model includes acquiring additional licenses to programs with third-party funding. For more information, visit www.xoma.com.
All references to “portfolio” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” in XOMA’s posts refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates in XOMA’s posts strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.
Location: United States, California, Emeryville
Employees: 11-50
Founded date: 1981
Investors 2
Date | Name | Website |
- | Hercules C... | htgc.com |
- | Ignite 500 | ignite500.... |
Mentions in press and media 14
Date | Title | Description | Source |
03.04.2024 | XOMA Corporation Announces Closing of Tender Offer | Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right EMERYVILLE, Ca... | einpresswi... |
08.03.2024 | XOMA Reports Fourth Quarter and Full Year 2023 Financial Res... | - | globenewsw... |
07.01.2023 | XOMA Announces New Employment Inducement Grants Under Nasdaq... | EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation XOMA ("XOMA" or the... | einpresswi... |
07.09.2022 | XOMA to Present at H.C. Wainwright 24th Annual Global Invest... | EMERYVILLE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnol... | globenewsw... |
04.08.2022 | XOMA Reports Second Quarter 2022 Financial Results and Highl... | The completion of Regeneron’s acquisition of Checkmate Pharmaceuticals resulted in a $5 million mile... | globenewsw... |
20.06.2022 | XOMA Declares Quarterly Preferred Stock Dividends | EMERYVILLE, Calif., June 20, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the... | globenewsw... |
22.12.2021 | XOMA : 2021 Year-end Letter to Shareholders | Dear Shareholders and Friends, As we close out 2021 and look forward to all the possibilities 2022 w... | marketscre... |
21.12.2021 | XOMA to Present at Upcoming Investor Conferences | EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), a biotechnolo... | marketscre... |
07.04.2021 | XOMA CORPORATION XOMA Prices $35 Million Offering of Deposi... | EMERYVILLE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or th... | marketscre... |
10.03.2021 | XOMA CORPORATION XOMA Reports Fourth Quarter and Full-Year ... | Recognized revenue of $29.4 million Six assets in the Company’s milestone and royalty portfolio adva... | marketscre... |
Show more